What is the recommended management for pheochromocytoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Pheochromocytoma

Definitive Treatment

Surgical resection via laparoscopic adrenalectomy is the only curative treatment for pheochromocytoma and should be performed after 10-14 days of preoperative alpha-adrenergic blockade. 1, 2, 3


Preoperative Medical Preparation

Alpha-Adrenergic Blockade (MANDATORY)

  • Initiate alpha-blockade immediately upon biochemical confirmation and continue for 10-14 days before surgery 1, 2, 3
  • Target blood pressure: <130/80 mmHg supine AND systolic >90 mmHg when standing 1, 2, 3

Choice of Alpha-Blocker:

  • Phenoxybenzamine (non-selective, non-competitive): FDA-approved for pheochromocytoma; may provide superior intraoperative hemodynamic stability and better alpha-blockade 4, 5
  • Selective alpha-1 blockers (doxazosin, prazosin, terazosin): Equally effective alternatives with fewer side effects (less orthostatic hypotension, edema, nasal congestion) but may require more additional antihypertensive agents 6, 1, 7

The 2024 ESC guidelines note that both phenoxybenzamine and selective alpha-1 blockers are effective, with phenoxybenzamine potentially providing less intraoperative hemodynamic instability 6. However, recent research shows phenoxybenzamine costs significantly more ($442/day vs $5/day for doxazosin) without clear superiority in preventing cardiovascular complications 5.

Beta-Blockade (ONLY AFTER Alpha-Blockade)

  • NEVER initiate beta-blockers before adequate alpha-blockade—this can precipitate hypertensive crisis from unopposed alpha-adrenergic stimulation 1, 3
  • Add beta-blockers only after alpha-blockade is established to control reflex tachycardia and tachyarrhythmias 6, 1, 3

Adjunctive Therapies

  • Calcium channel blockers: Use as adjuncts for refractory hypertension or as monotherapy in normotensive/mildly hypertensive patients 6, 1, 3
  • Metyrosine (alpha-methyltyrosine): Catecholamine synthesis inhibitor that may improve intraoperative blood pressure control, reduce blood loss, and decrease fluid requirements when combined with phenoxybenzamine 8, 9

Volume Expansion

  • High-sodium diet and 1-2 liters of saline 24 hours before surgery, plus compression stockings, to prevent orthostatic and postoperative hypotension 1, 3
  • Phenoxybenzamine induces significant plasma volume expansion (+14.5%) which counteracts the peripheral hypovolemia characteristic of pheochromocytoma 10

Surgical Approach

Technique Selection

  • Laparoscopic adrenalectomy is preferred for most pheochromocytomas 6, 1, 2, 3
  • Open surgery for: tumors >6 cm, high suspicion of malignancy, or local invasion 1, 3
  • Complete R0 resection is the only potentially curative approach 1, 2, 3

Bilateral Disease Considerations

  • Resect functional tumors first due to perioperative hypertensive crisis risk 1
  • Consider cortical-sparing techniques in hereditary syndromes to preserve adrenal function, but weigh against risk of incomplete resection 1

Intraoperative Management

Hypertensive Crisis Treatment

  • Phentolamine (IV alpha-1 blocker): First-line for adrenergic crises 6, 1
  • Alternatives: Magnesium sulfate, calcium antagonists, nitroprusside, nitroglycerin 6, 1, 2
  • Labetalol (IV): 1-2 mg/kg bolus followed by continuous infusion; provides both alpha and beta blockade, avoiding tachycardia 6

Tachycardia Management

  • Esmolol (IV beta-blocker) for intraoperative tachycardia 1, 2

Hypotension Management

  • Aggressive fluid resuscitation for postoperative hypotension 1, 2, 3
  • Anticipate hypotension after tumor removal due to sudden catecholamine withdrawal and peripheral hypovolemia 6

Postoperative Care

Immediate Monitoring

  • Monitor glucose levels closely—hypoglycemia commonly occurs after catecholamine levels drop 1, 2, 3
  • Aggressive treatment of hypotension with fluids 1, 2

Biochemical Confirmation

  • Measure plasma or urine metanephrines at 2-8 weeks post-surgery to confirm complete tumor removal 1, 2, 3
  • Imaging at 3-6 months to verify complete resection 1

Long-Term Surveillance

Follow-Up Protocol

  • Lifelong surveillance required due to 10-15% recurrence risk 2
  • Clinical monitoring (blood pressure, adrenergic symptoms): Every 3-4 months for 2-3 years, then every 6 months 2
  • Biochemical testing (plasma/urine metanephrines, chromogranin A): Every 3-4 months for 2-3 years, then every 6 months 2
  • Imaging: At 3-6 months post-treatment, then periodically based on risk stratification 1
  • Minimum 10 years of surveillance for all patients 1

Critical Pitfalls to Avoid

  • NEVER perform fine needle biopsy of suspected pheochromocytoma—can precipitate fatal hypertensive crisis 2, 3
  • NEVER start beta-blockers before alpha-blockade 1, 3
  • Do not proceed to surgery without adequate preoperative preparation (10-14 days of alpha-blockade) 1, 2, 3
  • Do not assume cure without biochemical confirmation at 2-8 weeks post-surgery 1, 2, 3

References

Guideline

Operative Management of Bilateral Pheochromocytoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Pheochromocytoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initial Treatment for Pheochromocytoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Comparison of Preoperative Alpha-blockade for Resection of Paraganglioma and Pheochromocytoma.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2022

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Preoperative treatment and survival of patients with pheochromocytomas.

Annales chirurgiae et gynaecologiae, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.